Range of published estimates of venous thromboembolism incidence in young women

Heinemann, L.; Dinger, Jürgen

doi:10.1016/j.contraception.2006.12.018

Cited by 118 publications

(59 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26 All studies we found of estrogen-containing contraceptive use and risk of venous thromboembolism included women of all reproductive ages (up to age 59 in one study 24 ), consistently noting age to be an independent risk factor. [19][20][21][22][23] Although arterial events are less common than venous thromboembolism in women of reproductive age, the sequelae of stroke and myocardial infarction may be more devastating than those of venous thromboembolism. A large Danish cohort study found that women aged 45-49 years had 20 times the risk of stroke and 100 times the risk of myocardial infarction as women aged [15][16][17][18][19].…”

Section: Cardiovascular Eventsmentioning

confidence: 99%

“…18 The incidence of venous thromboembolism among women of reproductive age has been reported to range from 5 to 10 per 10 000 woman-years, and the risk of venous thromboembolism increases with age. 19 Among women of reproductive age, the risk of venous thromboembolism among those who use estrogen-containing contraceptives is double that among nonusers (8-10 per 10 000 woman-years v. 4-5 per 10 000 woman-years). 20 However, pregnancy and the immediate postpartum period is associated with 3 times the risk of venous thromboembolism compared with the use of estrogen-containing contraceptives.…”

Section: Cardiovascular Eventsmentioning

confidence: 99%

See 1 more Smart Citation

Contraception in women over 40 years of age

Allen

Cwiak

Kaunitz

2013

CMAJ

View full text Add to dashboard Cite

Section: Cardiovascular Eventsmentioning

confidence: 99%

Section: Cardiovascular Eventsmentioning

confidence: 99%

Contraception in women over 40 years of age

Allen

Cwiak

Kaunitz

2013

CMAJ

View full text Add to dashboard Cite

“…Also, the combination of OC or HRT use with well-defined hereditary or acquired thrombophilic risk factors further increases the risk for VTE (68)(69)(70). According to the newer literature data, incidence of VTE in women of reproductive age who are not OC users is about 4-5/10 000 per year, with an approximate doubling of risk into the range of 9-10/10 000 for women who are OC users (71,72). However, despite of an increased relative risk in women on OC or HRT with and without thrombophilic risk factors, the absolute risk attributable to hormonal therapy remains low, especially in young women on OC (1,65,73).…”

Section: Women On Oral Contraceptives or Hormone Replacement Therapymentioning

confidence: 99%

Laboratory Investigation of Thrombophilia / LABORATORIJSKO ISPITIVANJE TROMBOFILIJA

Margetić¹

2014

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Summary: Laboratory investigation of thrombophilia is aimed at detecting the well-established hereditary and acquired causes of venous thromboembolism, including activated protein C resistance/factor V Leiden mutation, prothrombin G20210A mutation, deficiencies of the physiological anticoagulants antithrombin, protein C and protein S, the presence of antiphospholipid antibodies and increased plasma levels of homocysteine and coagulation factor VIII. In contrast, investigation of dysfibrinogenemia, a very rare thrombophilic risk factor, should only be considered in a patient with evidence of familial or recurrent thrombosis in the absence of all evaluated risk factors mentioned above. At this time, thrombophilia investigation is not recommended for other potential hereditary or acquired risk factors whose association with increased risk for thrombosis has not been proven sufficiently to date. In order to ensure clinical relevance of testing and to avoid any misinterpretation of results, laboratory investigation of thrombophilia should always be performed in accordance with the recommended guidelines on testing regarding the careful selection of patients, time of testing and assays and assay methods used. The aim of this review is to summarize the most important aspects on thrombophilia testing, including whom and when to test, what assays and assay methods to use and all other variables that should be considered when performing laboratory investigation of thrombophilia.Keywords: acquired risk factors, hereditary risk factors, laboratory investigation of thrombophilia, venous thromboembolism Sa`etak: Cilj laboratorijskog ispitivanja trombofilije je otkrivanje ve} ustanovljenih naslednih i ste~enih uzroka venskog tromboembolizma, me|u kojima su aktivirana rezistencija na protein C/mutacija faktora V Leiden, mutacija protrombina G20210A, deficijencija fiziolo{kih antikoagulanasa antitrombina, proteina C i proteina S, prisustvo antifosfolipidnih antitela i povi{enih nivoa homocisteina i faktora koagulacije VIII u plazmi. Nasuprot tome, ispitivanje disfibrinogenemije, veoma retkog faktora rizika za trombofiliju, treba uzeti u razmatranje samo kod pacijenata kod kojih postoje dokazi o porodi~noj ili rekurentnoj trombozi uz odsustvo svih navedenih faktora rizika. U ovom trenutku, ispitivanje trombofilije se ne preporu~uje za ostale potencijalne nasledne ili ste~ene faktore rizika, ~ija povezanost sa pove}anim rizikom za trombozu jo{ nije nedvosmisleno dokazana. Kako bi se obezbedila klini~ka relevantnost testiranja i izbeglo pogre{no tuma~enje rezultata, laboratorijsko ispitivanje trombofilije trebalo bi uvek vr{iti u skladu s preporukama za testiranje koje se odnose na pa`ljiv odabir pacijenata, vreme testiranja i testove i metode koji se koriste. Cilj ovog preglednog ~lanka je da se ukratko predstave najva`niji aspekti testiranja trombofilije, izme|u ostalog, koga i kada testirati, koje testove i metode upotrebiti i koje sve varijable treba uzeti u obzir prilikom laboratorijskog ispitivanja trombofilije.Klju~ne rije~i...

show abstract

“…While lowering of the estrogen dose in newer pills to 10 -20 μg per tablet may further reduce the risk of VTE [39] [69] there is, to date, no compelling evidence to support this premise. Contemporary combined hormonal contraceptives are estimated to double the background risk of VTE from 4 -5/10,000 to approximately 9 -10/10,000 women years [3] [70].…”

Section: Combined Hormonal Contraceptivesmentioning

confidence: 99%

“…They suggested that the variation in quoted risk was partly due to differences in methodology as well as definitions of VTE and the sensitivity of diagnostic tests over time. However they concluded in their analysis that the true incidence in women not using hormonal contraception was approximately 4 -5 per 10,000 women years [3]. This article will highlight important clinical considerations for HCPs with regard to VTE risk and contraception.…”

mentioning

confidence: 99%

Contraception and Venous Thromboembolism: Risk Factors and Clinical Considerations

Waddington¹,

Ferguson²,

Reid³

2017

OJOG

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a known risk with some forms of hormonal contraception, and should be considered by health care providers when counselling patients about their contraceptive options. Various other risk factors exist for VTE, including family history of VTE and a personal history of VTE or thrombophilia. This article will summarize various known risk factors for VTE, as well as what is known about the VTE risk imparted by the use of different contraceptives.

show abstract

Range of published estimates of venous thromboembolism incidence in young women

Cited by 118 publications

References 33 publications

Contraception in women over 40 years of age

Contraception in women over 40 years of age

Laboratory Investigation of Thrombophilia / LABORATORIJSKO ISPITIVANJE TROMBOFILIJA

Contraception and Venous Thromboembolism: Risk Factors and Clinical Considerations

Contact Info

Product

Resources

About